lung cancer

Question 1

Therapy of choice for limited/resectable NSCLC

Answer 1

Surgery followed by adjuvant chemo with cisplatin + vincristine x4 cycles

Question 2

Therapy of choice for limited but unresectable NSCLC

Answer 2

Radiation + chemo (cisplatin + etoposide or pacelitaxel)

Question 3

1st line TKIs for metastatic NSCLC with adenocarcinoma histology with EGFR+ mutation

Answer 3

Erlitinib, afatinib, gefitinib

Question 4

1st line TKI for metastatic NSCLC with adenocarcinoma histology with ALK+ mutation or ROS-1+ mutation

Answer 4

Cizotinib

Question 5

2nd line EGFR-targeted therapy that is directed at T790M for treatment of metastatic NSCLC ademnocarcinoma histology that has progressed on EGFR-targeted TKI

Answer 5

Oslimertinib

Question 6

2nd line ALK TKIs for treatment of metastatic NSCLC adenocarcinoma histology

Answer 6

Ceritinib

Alectinib

Question 7

metastatic NSCLC with no mutation adenocarcinoma, use ciplatin + ________ x 4-6 cycles

Answer 7

pemetrexed or paclitaxel + bevacizumab

Question 8

Metastatic NSCLC squamous cell with no mutations, use cisplatin + ________ x 4-6 cycles

Answer 8

gemcitabine (+/- necitumumab) OR
nab-paclitaxel OR
Docetaxel

Question 9

3 drugs that are used in initial treatment of metastatic NSCLC with no mutations that should be continued onto maintenance therapy

Answer 9

pemetrexed, bevacizumab and necitumumab

Question 10

Gold standard 2nd line therapy for metastatic NSCLC after progression following platinum-based chemo

Answer 10

Nivolumab or pemrolizumab

Question 11

MOA of nicvolumab and pembrolizumab

Answer 11

Ab against PD-1 receptor

Question 12

Preferred treatment for limited stage SCLC

Answer 12

Chemo (cisplatin + etoposide) + radiation

Question 13

1st line treatment for extensive disease SCLC

Answer 13

Cisplatin/carboplatin + etoposide x 4-6 cycles

use carboplatin in renal dysfunction

Question 14

2 risk factor for lung cancer

Answer 14

Radon exposure